IL301912A - System and method for removal of immune inhibitors from biological fluids - Google Patents

System and method for removal of immune inhibitors from biological fluids

Info

Publication number: IL301912A
Authority: IL; Israel
Prior art keywords: column; capture; tnf; plasma; stnf
Prior art date: 2019-11-19

Application number

IL301912A

Other languages

English (en)

Hebrew (he)

Original Assignee

Immunicom Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-11-19

Filing date

2019-11-19

Publication date

2023-06-01

2019-11-19 Application filed by Immunicom Inc filed Critical Immunicom Inc

2023-06-01 Publication of IL301912A publication Critical patent/IL301912A/en

Links

238000000034 method Methods 0.000 title description 54
239000013060 biological fluid Substances 0.000 title description 2
229960003444 immunosuppressant agent Drugs 0.000 title 1
239000003018 immunosuppressive agent Substances 0.000 title 1
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 23
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 20
238000002386 leaching Methods 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 17
239000000178 monomer Substances 0.000 claims description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 6
102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 6
102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 5
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 3
102000003390 tumor necrosis factor Human genes 0.000 claims 5
239000003446 ligand Substances 0.000 description 97
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 76
102100040247 Tumor necrosis factor Human genes 0.000 description 76
239000011324 bead Substances 0.000 description 74
230000027455 binding Effects 0.000 description 71
230000014759 maintenance of location Effects 0.000 description 67
210000001124 body fluid Anatomy 0.000 description 55
239000010839 body fluid Substances 0.000 description 55
238000011282 treatment Methods 0.000 description 48
210000004369 blood Anatomy 0.000 description 39
239000008280 blood Substances 0.000 description 39
206010028980 Neoplasm Diseases 0.000 description 38
108090000623 proteins and genes Proteins 0.000 description 35
102000004169 proteins and genes Human genes 0.000 description 34
-1 alanine amino acids Chemical class 0.000 description 32
238000002617 apheresis Methods 0.000 description 32
235000018102 proteins Nutrition 0.000 description 31
201000011510 cancer Diseases 0.000 description 24
239000011159 matrix material Substances 0.000 description 24
102000005962 receptors Human genes 0.000 description 24
108020003175 receptors Proteins 0.000 description 24
239000000463 material Substances 0.000 description 23
235000001014 amino acid Nutrition 0.000 description 21
229940024606 amino acid Drugs 0.000 description 20
239000007787 solid Substances 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 17
239000012530 fluid Substances 0.000 description 17
238000012360 testing method Methods 0.000 description 16
239000003153 chemical reaction reagent Substances 0.000 description 14
230000006870 function Effects 0.000 description 13
241000282465 Canis Species 0.000 description 12
239000012528 membrane Substances 0.000 description 12
238000006467 substitution reaction Methods 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
125000006850 spacer group Chemical group 0.000 description 9
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
230000004913 activation Effects 0.000 description 8
238000001042 affinity chromatography Methods 0.000 description 8
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 8
231100000682 maximum tolerated dose Toxicity 0.000 description 8
239000004417 polycarbonate Substances 0.000 description 8
229920000515 polycarbonate Polymers 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000006722 reduction reaction Methods 0.000 description 8
238000001228 spectrum Methods 0.000 description 8
230000004083 survival effect Effects 0.000 description 8
229920000936 Agarose Polymers 0.000 description 7
101800001271 Surface protein Proteins 0.000 description 7
230000001093 anti-cancer Effects 0.000 description 7
230000000259 anti-tumor effect Effects 0.000 description 7
239000012472 biological sample Substances 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
230000008878 coupling Effects 0.000 description 7
238000010168 coupling process Methods 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
238000010494 dissociation reaction Methods 0.000 description 7
230000005593 dissociations Effects 0.000 description 7
238000010828 elution Methods 0.000 description 7
238000003780 insertion Methods 0.000 description 7
230000037431 insertion Effects 0.000 description 7
229960005386 ipilimumab Drugs 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000005259 measurement Methods 0.000 description 7
238000002616 plasmapheresis Methods 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
239000011148 porous material Substances 0.000 description 7
230000004044 response Effects 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000007792 addition Methods 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
238000006268 reductive amination reaction Methods 0.000 description 6
230000008929 regeneration Effects 0.000 description 6
238000011069 regeneration method Methods 0.000 description 6
230000001954 sterilising effect Effects 0.000 description 6
238000004659 sterilization and disinfection Methods 0.000 description 6
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
239000004743 Polypropylene Substances 0.000 description 5
230000002411 adverse Effects 0.000 description 5
239000007853 buffer solution Substances 0.000 description 5
230000028993 immune response Effects 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
201000001441 melanoma Diseases 0.000 description 5
229920001155 polypropylene Polymers 0.000 description 5
230000008569 process Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
238000000926 separation method Methods 0.000 description 5
235000004400 serine Nutrition 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
108090001008 Avidin Proteins 0.000 description 4
239000004793 Polystyrene Substances 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000002591 computed tomography Methods 0.000 description 4
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 4
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 4
229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
125000005647 linker group Chemical group 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
239000012071 phase Substances 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
229920002223 polystyrene Polymers 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000001195 ultra high performance liquid chromatography Methods 0.000 description 4
IEJPPSMHUUQABK-UHFFFAOYSA-N 2,4-diphenyl-4h-1,3-oxazol-5-one Chemical compound O=C1OC(C=2C=CC=CC=2)=NC1C1=CC=CC=C1 IEJPPSMHUUQABK-UHFFFAOYSA-N 0.000 description 3
HQWDKLAIDBOLFE-UHFFFAOYSA-M 2-fluoro-1-methylpyridin-1-ium;4-methylbenzenesulfonate Chemical compound C[N+]1=CC=CC=C1F.CC1=CC=C(S([O-])(=O)=O)C=C1 HQWDKLAIDBOLFE-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
239000004971 Cross linker Substances 0.000 description 3
229920001780 ECTFE Polymers 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000010100 anticoagulation Effects 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
235000009582 asparagine Nutrition 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
235000003704 aspartic acid Nutrition 0.000 description 3
230000003385 bacteriostatic effect Effects 0.000 description 3
238000004422 calculation algorithm Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000000539 dimer Substances 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
230000004927 fusion Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
230000006028 immune-suppresssive effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
239000000203 mixture Substances 0.000 description 3
208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
229920002492 poly(sulfone) Polymers 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
229920001343 polytetrafluoroethylene Polymers 0.000 description 3
239000004810 polytetrafluoroethylene Substances 0.000 description 3
238000002600 positron emission tomography Methods 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
230000005855 radiation Effects 0.000 description 3
238000005070 sampling Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
239000004474 valine Substances 0.000 description 3
230000002792 vascular Effects 0.000 description 3
CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
108091023037 Aptamer Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241001432959 Chernes Species 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
239000004593 Epoxy Substances 0.000 description 2
108010075944 Erythropoietin Receptors Proteins 0.000 description 2
102100036509 Erythropoietin receptor Human genes 0.000 description 2
101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
238000010976 amide bond formation reaction Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000005975 antitumor immune response Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
150000001483 arginine derivatives Chemical class 0.000 description 2
150000001510 aspartic acids Chemical class 0.000 description 2
238000012575 bio-layer interferometry Methods 0.000 description 2
239000012620 biological material Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000004227 calcium gluconate Substances 0.000 description 2
229960004494 calcium gluconate Drugs 0.000 description 2
235000013927 calcium gluconate Nutrition 0.000 description 2
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000000919 ceramic Substances 0.000 description 2
230000003196 chaotropic effect Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000012504 chromatography matrix Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
230000034994 death Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000012954 diazonium Substances 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
238000005401 electroluminescence Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000011010 flushing procedure Methods 0.000 description 2
229920001903 high density polyethylene Polymers 0.000 description 2
239000004700 high-density polyethylene Substances 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
125000001165 hydrophobic group Chemical group 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000005746 immune checkpoint blockade Effects 0.000 description 2
230000008102 immune modulation Effects 0.000 description 2
239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
102000002467 interleukin receptors Human genes 0.000 description 2
108010093036 interleukin receptors Proteins 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
229920001684 low density polyethylene Polymers 0.000 description 2
239000004702 low-density polyethylene Substances 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N p-toluenesulfonyl chloride Substances CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
229920000139 polyethylene terephthalate Polymers 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 2
238000010791 quenching Methods 0.000 description 2
208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000012487 rinsing solution Substances 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000002603 single-photon emission computed tomography Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
229920000638 styrene acrylonitrile Polymers 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
239000013638 trimer Substances 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
239000002699 waste material Substances 0.000 description 2
238000003466 welding Methods 0.000 description 2
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
102000009346 Adenosine receptors Human genes 0.000 description 1
108050000203 Adenosine receptors Proteins 0.000 description 1
229910000838 Al alloy Inorganic materials 0.000 description 1
102000008873 Angiotensin II receptor Human genes 0.000 description 1
108050000824 Angiotensin II receptor Proteins 0.000 description 1
238000012371 Aseptic Filling Methods 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
102000008096 B7-H1 Antigen Human genes 0.000 description 1
108010074708 B7-H1 Antigen Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
102000005674 CCR Receptors Human genes 0.000 description 1
108010059983 CCR Receptors Proteins 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
108091011896 CSF1 Proteins 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
108091008928 CXC chemokine receptors Proteins 0.000 description 1
102000054900 CXCR Receptors Human genes 0.000 description 1
102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
102000018208 Cannabinoid Receptor Human genes 0.000 description 1
108050007331 Cannabinoid receptor Proteins 0.000 description 1
102000009410 Chemokine receptor Human genes 0.000 description 1
108050000299 Chemokine receptor Proteins 0.000 description 1
102000004859 Cholecystokinin Receptors Human genes 0.000 description 1
108090001085 Cholecystokinin Receptors Proteins 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102100026735 Coagulation factor VIII Human genes 0.000 description 1
101100285408 Danio rerio eng2a gene Proteins 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229910000640 Fe alloy Inorganic materials 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
102000007563 Galectins Human genes 0.000 description 1
108010046569 Galectins Proteins 0.000 description 1
108010063919 Glucagon Receptors Proteins 0.000 description 1
102100040890 Glucagon receptor Human genes 0.000 description 1
102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
102000000543 Histamine Receptors Human genes 0.000 description 1
108010002059 Histamine Receptors Proteins 0.000 description 1
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
108091008036 Immune checkpoint proteins Proteins 0.000 description 1
102000037982 Immune checkpoint proteins Human genes 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
239000004425 Makrolon Substances 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
108010056852 Myostatin Proteins 0.000 description 1
102000004472 Myostatin Human genes 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
102000015278 OSM-LIF Receptors Human genes 0.000 description 1
108010064527 OSM-LIF Receptors Proteins 0.000 description 1
102000012547 Olfactory receptors Human genes 0.000 description 1
108050002069 Olfactory receptors Proteins 0.000 description 1
102000003987 Oncostatin M Receptors Human genes 0.000 description 1
108010082522 Oncostatin M Receptors Proteins 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
241000906034 Orthops Species 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
239000004695 Polyether sulfone Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
101100371144 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) tsi7 gene Proteins 0.000 description 1
108010080192 Purinergic Receptors Proteins 0.000 description 1
102000000033 Purinergic Receptors Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100028927 Secretin receptor Human genes 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
108050001286 Somatostatin Receptor Proteins 0.000 description 1
102000011096 Somatostatin receptor Human genes 0.000 description 1
108010068542 Somatotropin Receptors Proteins 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
229920006355 Tefzel Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
150000003926 acrylamides Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
239000007844 bleaching agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
230000037396 body weight Effects 0.000 description 1
206010006007 bone sarcoma Diseases 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229910010293 ceramic material Inorganic materials 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011833 dog model Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000005931 immune cell recruitment Effects 0.000 description 1
229940126546 immune checkpoint molecule Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
238000011016 integrity testing Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000007769 metal material Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
108091005592 methylated proteins Proteins 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
102000027424 natriuretic peptide receptors Human genes 0.000 description 1
108091008599 natriuretic peptide receptors Proteins 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920006393 polyether sulfone Polymers 0.000 description 1
229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
229920005606 polypropylene copolymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000000722 protumoral effect Effects 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000010845 search algorithm Methods 0.000 description 1
108700027603 secretin receptor Proteins 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002594 sorbent Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010959 steel Substances 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
102000042286 type I cytokine receptor family Human genes 0.000 description 1
108091052247 type I cytokine receptor family Proteins 0.000 description 1
102000042287 type II cytokine receptor family Human genes 0.000 description 1
108091052254 type II cytokine receptor family Proteins 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Anesthesiology (AREA)
Cell Biology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Biodiversity & Conservation Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Physics & Mathematics (AREA)
Organic Chemistry (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
External Artificial Organs (AREA)

IL301912A 2019-11-19 2019-11-19 System and method for removal of immune inhibitors from biological fluids IL301912A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2019/062177 WO2021101519A1 (fr)	2019-11-19	2019-11-19	Système et méthode pour l'élimination d'inhibiteurs immunitaires de fluides biologiques

Publications (1)

Publication Number	Publication Date
IL301912A true IL301912A (en)	2023-06-01

Family

ID=75980821

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL301912A IL301912A (en)	2019-11-19	2019-11-19	System and method for removal of immune inhibitors from biological fluids
IL289438A IL289438B2 (en)	2019-11-19	2019-11-19	System and method for removing immunosuppressants from biological fluids

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL289438A IL289438B2 (en)	2019-11-19	2019-11-19	System and method for removing immunosuppressants from biological fluids

Country Status (8)

Country	Link
EP (1)	EP3846875A4 (fr)
JP (2)	JP7159493B2 (fr)
KR (2)	KR102491518B1 (fr)
CN (1)	CN114650852B (fr)
AU (3)	AU2019474912B2 (fr)
CA (2)	CA3153685C (fr)
IL (2)	IL301912A (fr)
WO (1)	WO2021101519A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11224858B1 (en)	2020-10-01	2022-01-18	Immunicom, Inc.	Reduced leaching of a ligand
WO2022071960A1 (fr) *	2020-10-01	2022-04-07	Immunicom, Inc.	Lixiviation réduite d'un ligand
JP7632141B2 (ja) *	2021-07-14	2025-02-19	東レ株式会社	モジュール

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2213079C (fr)	1995-02-16	2004-12-14	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	Adsorbant du facteur .alpha. de necrose tumorale, procede permettant de l'eliminer par adsorption et dispositif d'adsorption utilisant ledit adsorbant
US8197430B1 (en) *	1998-05-22	2012-06-12	Biopheresis Technologies, Inc.	Method and system to remove cytokine inhibitor in patients
JP4150838B2 (ja) *	1999-11-02	2008-09-17	株式会社カネカ	充填物流出防止用フィルタ及びそれを装着した吸着器
WO2004064608A2 (fr) *	2003-01-17	2004-08-05	Aethlon Medical, Inc.	Procede de suppression de virus dans le sang par hemodialyse a affinite pour les lectines
JP2006288571A (ja)	2005-04-08	2006-10-26	Toray Ind Inc	癌治療用吸着材および体外循環カラム
JP4925159B2 (ja) *	2005-10-12	2012-04-25	日機装株式会社	血液浄化装置
DK3789056T3 (da) *	2007-08-31	2025-06-23	Seastar Medical Inc	Indretninger til selektiv cytoferese
JP2009178523A (ja)	2008-02-01	2009-08-13	Kaneka Corp	可溶性腫瘍壊死因子受容体の吸着材、吸着方法および吸着装置
JP5341559B2 (ja)	2009-03-03	2013-11-13	和雄寺本	多孔性吸着材
US9717841B2 (en) *	2012-09-11	2017-08-01	Gary L. McNeil	Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
US9227005B2 (en)	2013-03-14	2016-01-05	Brian J LeBerthon	Method and device for treating cancer
US20170014450A1 (en)	2014-02-28	2017-01-19	Exosome Sciences, Inc.	Brain specific exosome based diagnostics and extracorporeal therapies
JP6480447B2 (ja) *	2014-07-22	2019-03-13	旭化成メディカル株式会社	ヒストンを除去する吸着材及び生体由来液浄化デバイス
JP2018509994A (ja)	2015-03-27	2018-04-12	エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	患者選択的アフェレシス
HUE064189T2 (hu)	2016-07-28	2024-02-28	Captec Medical Kft	Áramlásból befogó eszköz sejtek vérbõl történõ eltávolítására
US20190247560A1 (en) *	2018-02-13	2019-08-15	Gambro Lundia Ab	Extracorporeal devices and methods of treating complement factor related diseases
DE102018104177A1 (de) *	2018-02-23	2019-08-29	B. Braun Avitum Ag	Vorrichtung zur Entfernung von Noxen aus Blut, extrakorporales Perfusionssystem mit einer solchen Vorrichtung sowie Verfahren zur Herstellung einer solchen Vorrichtung
IL317026A (en) *	2018-02-28	2025-01-01	Plas Free Ltd	In vitro device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof

2019
- 2019-11-19 WO PCT/US2019/062177 patent/WO2021101519A1/fr not_active Ceased
- 2019-11-19 KR KR1020227003407A patent/KR102491518B1/ko active Active
- 2019-11-19 CA CA3153685A patent/CA3153685C/fr active Active
- 2019-11-19 AU AU2019474912A patent/AU2019474912B2/en active Active
- 2019-11-19 IL IL301912A patent/IL301912A/en unknown
- 2019-11-19 IL IL289438A patent/IL289438B2/en unknown
- 2019-11-19 CA CA3165330A patent/CA3165330A1/fr active Pending
- 2019-11-19 CN CN201980102088.9A patent/CN114650852B/zh active Active
- 2019-11-19 KR KR1020237002011A patent/KR20230016032A/ko not_active Ceased
- 2019-11-19 EP EP19920634.3A patent/EP3846875A4/fr not_active Withdrawn
- 2019-11-19 JP JP2021572881A patent/JP7159493B2/ja active Active
2022
- 2022-05-16 AU AU2022203249A patent/AU2022203249B2/en active Active
- 2022-10-12 JP JP2022163897A patent/JP7514281B2/ja active Active
2023
- 2023-11-29 AU AU2023274130A patent/AU2023274130A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3846875A1 (fr)	2021-07-14
JP2023015053A (ja)	2023-01-31
CA3165330A1 (fr)	2021-05-27
IL289438B2 (en)	2023-09-01
CN114650852B (zh)	2024-08-06
AU2019474912B2 (en)	2022-02-17
JP7159493B2 (ja)	2022-10-24
AU2022203249A1 (en)	2022-06-23
CA3153685A1 (fr)	2021-05-27
AU2019474912A1 (en)	2022-01-06
KR20220039724A (ko)	2022-03-29
KR20230016032A (ko)	2023-01-31
AU2023274130A1 (en)	2023-12-21
JP7514281B2 (ja)	2024-07-10
EP3846875A4 (fr)	2021-07-14
CA3153685C (fr)	2022-10-11
CN114650852A (zh)	2022-06-21
IL289438B1 (en)	2023-05-01
KR102491518B1 (ko)	2023-01-20
IL289438A (en)	2022-02-01
JP2022535604A (ja)	2022-08-09
WO2021101519A1 (fr)	2021-05-27
AU2022203249B2 (en)	2023-08-31

Publication	Publication Date	Title
AU2022203249B2 (en)	2023-08-31	System and method for removal of immune inhibitors from biological fluids
EP2717941B1 (fr)	2020-04-01	Traitement du cancer
CN1980696B (zh)	2012-09-26	除去病人体内可溶性tnfr1，tnfr2和il2的方法和系统
US20220288294A1 (en)	2022-09-15	System and method for removal of immune inhibitors from biological fluids
EA023912B1 (ru)	2016-07-29	Лечение воспалительных состояний
US20120323158A1 (en)	2012-12-20	Extracorporeal immunoadsorption treatment
US20070026029A1 (en)	2007-02-01	Apheresis device
TWI762833B (zh)	2022-05-01	自生物流體中移除免疫抑制劑之系統及方法
Olson	2020	Affinity chromatography
US11957825B2 (en)	2024-04-16	Modified TNF as a capture ligand
Raskova et al.	1979	Humoral inhibitors of the immune response in uremia. II. Further characterization of an immunosuppressive factor in uremic serum
WO2025122575A1 (fr)	2025-06-12	Traitement pour la modification d'une maladie
WO2012172340A2 (fr)	2012-12-20	Traitement de troubles mentaux